Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, held a virtual ground-breaking ceremony to celebrate the start of its large-scale cell culture expansion project. The major capital investment of $928 million from Fujifilm Corporation was previously announced in June 2020.   The expansion will double the existing bulk drug substance production capacity with the addition of 6 x 20,000L bioreactors, brin...